Data as of Mar 10
| 0.00 / 0.00%|
The 3 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 11.00 and a low estimate of 7.00. The median estimate represents a +138.10% increase from the last price of 3.36.
The current consensus among 4 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.